These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20032550)

  • 41. Dermatological aspects of medicine: highly active antiretroviral therapy and the treatment of human immunodeficiency virus.
    Finucane KA; Archer CB
    Clin Exp Dermatol; 2010 Jan; 35(1):107-9. PubMed ID: 19758384
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolic complications of HIV therapy in children.
    McComsey GA; Leonard E
    AIDS; 2004 Sep; 18(13):1753-68. PubMed ID: 15316336
    [No Abstract]   [Full Text] [Related]  

  • 43. HIV infection, body composition changes and related metabolic complications: contributing factors and evolving management strategies.
    Falutz J
    Curr Opin Clin Nutr Metab Care; 2011 May; 14(3):255-60. PubMed ID: 21460720
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Key data from the 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.
    Coughlan R; Cameron S
    Antivir Ther; 2016; 21(1):75-89. PubMed ID: 26857256
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HIV and increased risk of cardiovascular diseases.
    Das S
    Sex Health; 2005; 2(4):219-21. PubMed ID: 16402668
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Anaesthesia for HIV-infected patients].
    Bornard L; Blay M; Roger PM; Raucoules-Aimé M; Carles M
    Ann Fr Anesth Reanim; 2011 Jun; 30(6):501-11. PubMed ID: 21684100
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Key data from the 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 6-8 November 2008, London, UK.
    Tadayyon M; Cameron S
    Antivir Ther; 2008; 13(8):1115-27. PubMed ID: 19195338
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [HIV infection in France in 2012: reality, risks and challenges for a chronic multisystem disease].
    Blot M; Piroth L
    Rev Mal Respir; 2012 Jun; 29(6):785-92. PubMed ID: 22742465
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inflammation and complications of HIV disease.
    Dubé MP; Sattler FR
    J Infect Dis; 2010 Jun; 201(12):1783-5. PubMed ID: 20446849
    [No Abstract]   [Full Text] [Related]  

  • 50. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA 22-25 September 2002.
    Nolan D; Christiansen F
    Expert Opin Drug Saf; 2003 Jan; 2(1):95-101. PubMed ID: 12904128
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Update from the 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV.
    Brown T; Confrancesco J
    Hopkins HIV Rep; 2005 Jan; 17(1):4-5, 8. PubMed ID: 16419320
    [No Abstract]   [Full Text] [Related]  

  • 52. Complications of HIV disease and antiretroviral therapy.
    Currier JS; Havlir DV
    Top HIV Med; 2005; 13(1):16-23. PubMed ID: 15849369
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Growth hormone and HIV infection: contribution to disease manifestations and clinical implications.
    Falutz J
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):517-29. PubMed ID: 21663844
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular risk markers are increased in HIV-infected children with lipodystrophy syndrome.
    Guzmán-Fulgencio M; Micheloud D; Lorente R; Bellón JM; Gomez MI; Gurbindo MD; León JA; Muñoz-Fernández MÁ; Resino S
    J Infect; 2011 Mar; 62(3):240-3. PubMed ID: 21256862
    [No Abstract]   [Full Text] [Related]  

  • 55. ART regimes and fat: the healing hand wielding the sword.
    Domingo P; Espinet J; Vidal F
    Lancet HIV; 2017 Jan; 4(1):e2-e3. PubMed ID: 27815067
    [No Abstract]   [Full Text] [Related]  

  • 56. Report from Boston: the 12th Conference on Retroviruses and Opportunistic Infections (CROI). February 22-25, 2005. Complications/toxicity of HIV therapy.
    Moore RD; Cofrancesco J
    HIV Clin Trials; 2005; 6(4):229-34. PubMed ID: 16214738
    [No Abstract]   [Full Text] [Related]  

  • 57. Current advances in pharmacovigilance in the USA and Europe: meeting the challenges of safety monitoring in HIV.
    Marcus KA; Sorbello A; Truffa M; Williams J; Raine JM; Powderly WG
    Curr Opin HIV AIDS; 2012 Jul; 7(4):292-8. PubMed ID: 22647589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pharmaceutical follow up of antirretroviral treatment in outpatients].
    Moya Y; Bernal F; Rojas E; Barthel E
    Rev Chilena Infectol; 2012 Aug; 29(4):412-9. PubMed ID: 23096541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HIV-associated neurocognitive disease continues in the antiretroviral era.
    Clifford DB
    Top HIV Med; 2008; 16(2):94-8. PubMed ID: 18591717
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Report from the 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV.
    Zuger A
    AIDS Clin Care; 2009 Jan; 21(1):9. PubMed ID: 19226671
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.